Joint Statement (DZK, DGRh, DDG) on the Tuberculosis Risk with Treatment Using Novel Non-TNF-Alpha Biologicals

Abstract

Background While the risk of tuberculosis (TB) reactivation is adequately documented in relation to TNF-alpha inhibitors (TNFi), the question of what the tuberculosis risk is for newer, non-TNF biologics (non-TNFi) has not been thoroughly addressed.

Methods We conducted a systematic review of randomized phase 2 and phase 3 studies, and long-term extensions of same, published through March 2019. Of interest was information pertaining to screening and treating of latent tuberculosis (LTBI) in association with the use of 12 particular non-TNFi. Only rituximab was excluded. We searched MEDLINE and the ClinicalTrial.gov database for any and all candidate studies meeting these criteria.

Results 677 citations were retrieved; 127 studies comprising a total of 34,293 patients who received non-TNFi were eligible for evaluation. Only 80 out of the 127 studies, or 63 %, captured active TB (or at least opportunistic diseases) as potential outcomes and 25 TB cases were reported. More than two thirds of publications (86/127, 68 %) mentioned LTBI screening prior to inclusion of study participants in the respective trial, whereas in only 4 studies LTBI screening was explicitly considered redundant. In 21 studies, patients with LTBI were generally excluded from the trials and in 42 out of the 127 trials, or 33 %, latently infected patients were reported to receive preventive therapy (PT) at least 3 weeks prior to non-TNFi treatment.

Conclusions The lack of information in many non-TNFi studies on the number of patients with LTBI who were either excluded prior to participating or had been offered PT hampers assessment of the actual TB risk when applying the novel biologics. Therefore, in case of insufficient information about drugs or drug classes, the existing recommendations of the German Central Committee against Tuberculosis should be applied in the same way as is done prior to administering TNFi. Well designed, long-term “real world” register studies on TB progression risk in relation to individual substances for IGRA-positive cases without prior or concomitant PT may help to reduce selection bias and to achieve valid conclusions in the future.

Zusammenfassung

Hintergrund Während das Risiko einer Reaktivierung der Tuberkulose (TB) durch TNF-alpha-Inhibitoren (TNFi) hinreichend dokumentiert ist, kann das Tuberkulose-Risiko beim Einsatz neuerer Nicht-TNFi-Biologika bislang nur unzureichend eingeschätzt werden.

Methoden Wir führten ein systematisches Review zu 12 Nicht-TNFi-Biologika durch und bezogen alle randomisierten Phase-2- und Phase-3-Originalstudien sowie deren Anschlussstudien ein, die bis März 2019 veröffentlicht wurden. Nur Rituximab wurde ausgeschlossen. Im Mittepunkt des Interesses standen Informationen zum Screening auf und zur Behandlung von latenter Tuberkulose (LTBI). Durchsucht wurden die MEDLINE-Datenbank und das ClinicalTrial.gov-Register.

Ergebnisse 677 Publikationen wurden ermittelt, von denen 127 Studien mit insgesamt 34 293 Patienten, die Nicht-TNFi-Biologika erhalten hatten, evaluiert werden konnten. Nur in 80 der 127 Studien (63 %) war eine Tuberkulose (oder zumindest opportunistische Krankheiten) als potenzielle Nebenwirkung überhaupt erfasst worden; insgesamt wurden 25 TB-Fälle gemeldet. Mehr als ⅔ der Veröffentlichungen (86/127, 68 %) erwähnten ein LTBI-Screening vor Einbeziehung der Probanden in die jeweilige Studie, während ein LTBI-Screening in nur 4 Studien ausdrücklich als redundant angesehen wurde. In 21 Studien wurden Patienten mit LTBI grundsätzlich von der Studienteilnahme ausgeschlossen, und in 42 der 127 Studien (33 %) wurde berichtet, dass latent infizierte Patienten mindestens 3 Wochen vor der Nicht-TNFi-Behandlung eine präventive Therapie erhalten hatten.

Schlussfolgerungen Der Mangel an Informationen hinsichtlich der Zahl der Patienten mit LTBI, die entweder vor der Teilnahme an einer Studie mit Nicht-TNFi-Biologika ausgeschlossen wurden oder denen eine präventive Therapie angeboten wurde, erschwert die Einschätzung des tatsächlichen TB-Risikos beim Einsatz der neuen Substanzen. Bei unzureichenden Informationen über das Studiendesign bei neuen Biologika oder Biologika-Arten sollten daher die bestehenden Empfehlungen des Deutschen Zentralkomitees gegen Tuberkulose in gleicher Weise angewendet werden wie vor der Verabreichung von TNFi. Gut konzipierte Langzeitregisterstudien zum TB-Progressionsrisiko bei IGRA-positiven Patienten ohne vorherige oder begleitende präventive Therapie könnten dazu beitragen, einen Selektionsbias zu vermeiden und valide Schlussfolgerungen zu ermöglichen.

Publication History

Received: 12 October 2020

Accepted: 12 October 2020

Article published online:
17 February 2021

• References

• 1 Zhang Z, Fan W, Yang G. et al. Risk of tuberculosis in patients treated with TNF-α antagonists: a systematic review and meta-analysis of randomised controlled trials. BMJ Open 2017; 7: e012567
• 2 Singh JA, Wells GA, Christensen R. et al. Adverse effects of biologics: a network meta-analysis and Cochrane overview. Cochrane Database Syst Rev 2011; (02) Cd008794
• 3 Souto A, Maneiro JR, Salgado E. et al. Risk of tuberculosis in patients with chronic immune-mediated inflammatory diseases treated with biologics and tofacitinib: a systematic review and meta-analysis of randomized controlled trials and long-term extension studies. Rheumatology (Oxford) 2014; 53: 1872-1885
• 4 Diel R, Hauer B, Loddenkemper R. et al. Empfehlungen für das Tuberkulosescreening vor Gabe von TNF-alpha-Inhibitoren bei rheumatischen Erkrankungen [Recommendations for tuberculosis screening before initiation of TNF-alpha-inhibitor treatment in rheumatic diseases]. Pneumologie 2009; 63: 329-334
• 5 Frisell T, Dehlin M, Di Giuseppe D. et al. Comparative effectiveness of abatacept, rituximab, tocilizumab and TNFi biologics in RA: results from the nationwide Swedish register. Rheumatology 2019; 58: 1367-1377
• 6 Buch MH, Smolen JS, Betteridge N. et al. Updated consensus statement on the use of rituximab in patients with rheumatoid arthritis. Ann Rheum Dis 2011; 70: 909-920
• 7 Bathon J, Robles M, Ximenes AC. et al. Sustained disease remission and inhibition of radiographic progression in methotrexate-naive patients with rheumatoid arthritis and poor prognostic factors treated with abatacept: 2-year outcomes. Ann Rheum Dis 2011; 70: 1949-1956
• 8 Kremer JM, Dougados M, Emery P. et al. Treatment of rheumatoid arthritis with the selective costimulation modulator abatacept: twelve-month results of a phase iib, double-blind, randomized, placebo-controlled trial. Arthritis Rheum 2005; 52: 2263-2271
• 9 Kremer JM, Genant HK, Moreland LW. et al. Effects of abatacept inpatients with methotrexate-resistant active rheumatoid arthritis: a randomized trial. Ann Intern Med 2006; 144: 865-876
• 10 Kremer JM, Genant HK, Moreland LW. et al. Results of a two-year followup study of patients with rheumatoid arthritis who received a combination of abatacept and methotrexate. Arthritis Rheum 2008; 58: 953-963
• 11 Kremer JM, Russell AS, Emery P. et al. Long-term safety, efficacy and inhibition of radiographic progression with abatacept treatment in patients with rheumatoid arthritis and an inadequate response to methotrexate: 3-year results from the AIM trial. Ann Rheum Dis 2011; 70: 1826-1830
• 12 Lovell DJ, Ruperto N, Mouy R. et al.; Pediatric Rheumatology Collaborative Study Group and the Paediatric Rheumatology International Trials Organisation. Long-term safety, efficacy, and quality of life in patients with juvenile idiopathic arthritis treated with intravenous abatacept for up to seven years. Arthritis Rheumatol 2015; 67: 2759-2770
• 13 Ruperto N, Lovell DJ, Quartier P. et al.; Paediatric Rheumatology INternational Trials Organization; Pediatric Rheumatology Collaborative Study Group. Abatacept in children with juvenile idiopathic arthritis: a randomised, double-blind, placebo-controlled withdrawal trial. Lancet 2008; 372: 383-391
• 14 Ruperto N, Lovell DJ, Quartier P. et al. Long-term safety and efficacy of abatacept in children with juvenile idiopathic arthritis. Arthritis Rheum 2010; 62: 1792-1802
• 15 Schiff M, Keiserman M, Codding C. et al. Efficacy and safety of abatacept or infliximab vs placebo in ATTEST: a phase III, multi-centre, randomised, double-blind, placebo-controlled study in patients with rheumatoid arthritis and an inadequate response to methotrexate. Ann Rheum Dis 2008; 67: 1096-1103
• 16 Westhovens R, Robles M, Ximenes AC. et al. Clinical efficacy and safety of abatacept in methotrexate-naive patients with early rheumatoid arthritis and poor prognostic factors. Ann Rheum Dis 2009; 68: 1870-1877
• 17 Westhovens R, Kremer JM, Moreland LW. et al. Safety and efficacy of the selective costimulation modulator abatacept in patients with rheumatoid arthritis receiving background methotrexate: a 5-year extended phase IIB study. J Rheumatol 2009; 36: 736-742
• 18 Westhovens R, Kremer JM, Emery P. et al. Long-term safety and efficacy of abatacept in patients with rheumatoid arthritis and an inadequate response to methotrexate: a 7-year extended study. Clin Exp Rheumatol 2014; 32: 553-562 Epub 2014 Jul 8. PubMed PMID: 25005467
• 19 Fleischmann RM, Schechtman J, Bennett R. et al. Anakinra, a recombinant human interleukin-1 receptor antagonist (r-metHuIL-1ra), in patients with rheumatoid arthritis: A large, international, multicenter, placebo-controlled trial. Arthritis Rheum 2003; 48: 927-934
• 20 Ilowite N, Porras O, Reiff A. et al. Anakinra in the treatment of polyarticular-course juvenile rheumatoid arthritis: safety and preliminary efficacy results of a randomized multicenter study. Clin Rheumatol 2009; 28: 129-137
• 21 Fleischmann RM, Tesser J, Schiff MH. et al. Safety of extended treatment with anakinra in patients with rheumatoid arthritis. Ann Rheum Dis 2006; 65: 1006-1012
• 22 Tzanetakou V, Kanni T, Giatrakou S. et al. Safety and Efficacy of Anakinra in Severe Hidradenitis Suppurativa: A Randomized Clinical Trial. JAMA Dermatol 2016; 152: 52-59
• 23 Crowley J, Thaçi D, Joly P. et al. Long-term safety and tolerability of apremilast in patients with psoriasis: Pooled safety analysis for ≥ 156 weeks from 2 phase 3, randomized, controlled trials (ESTEEM 1 and 2). J Am Acad Dermatol 2017; 77: 310-317.e1
• 24 Cutolo M, Myerson GE, Fleischmann RM. et al. A Phase III, Randomized, Controlled Trial of Apremilast in Patients with Psoriatic Arthritis: Results of the PALACE 2 Trial. J Rheumatol 2016; 43: 1724-1734
• 25 Edwards CJ, Blanco FJ, Crowley J. et al. Apremilast, an oral phosphodiesterase 4 inhibitor, in patients with psoriatic arthritis and current skin involvement: a phase III, randomised, controlled trial (PALACE 3). Ann Rheum Dis 2016; 75: 1065-1073
• 26 Kavanaugh A, Mease PJ, Gomez-Reino JJ. et al. Treatment of psoriatic arthritis in a phase 3 randomised, placebo-controlled trial with apremilast, an oral phosphodiesterase 4 inhibitor. Ann Rheum Dis 2014; 73: 1020-1026
• 27 Kavanaugh A, Mease PJ, Gomez-Reino JJ. et al. Longterm (52-week) results of a phase III randomized, controlled trial of apremilast in patients with psoriatic arthritis. J Rheumatol 2015; 42: 479-488
• 28 Ohtsuki M, Okubo Y, Komine M. et al. Apremilast, an oral phosphodiesterase 4 inhibitor, in the treatment of Japanese patients with moderate to severe plaque psoriasis: Efficacy, safety and tolerability results from a phase 2b randomized controlled trial. J Dermatol 2017; 44: 873-884
• 29 Papp K, Cather JC, Rosoph L. et al. Efficacy of apremilast in the treatment of moderate to severe psoriasis: a randomised controlled trial. Lancet 2012; 380: 738-746
• 30 Papp KA, Kaufmann R, Thaçi D. et al. Efficacy and safety of apremilast in subjects with moderate to severe plaque psoriasis: results from a phase II, multicenter, randomized, double-blind, placebo-controlled, parallel-group, dose-comparison study. J Eur Acad Dermatol Venereol 2013; 27: e376-e383
• 31 Papp K, Reich K, Leonardi CL. et al. Apremilast, an oral phosphodiesterase 4 (PDE4) inhibitor, in patients with moderate to severe plaque psoriasis: Results of a phase III, randomized, controlled trial (Efficacy and Safety Trial Evaluating the Effects of Apremilast in Psoriasis [ESTEEM] 1). J Am Acad Dermatol 2015; 73: 37-49
• 32 Paul C, Cather J, Gooderham M. et al. Efficacy and safety of apremilast, an oral phosphodiesterase 4 inhibitor, in patients with moderate-to-severe plaque psoriasis over 52 weeks: a phase III, randomized controlled trial (ESTEEM 2). Br J Dermatol 2015; 173: 1387-1399
• 33 Reich K, Gooderham M, Green L. et al. The efficacy and safety of apremilast, etanercept and placebo in patients with moderate-to-severe plaque psoriasis: 52-week results from a phase IIIb, randomized, placebo-controlled trial (LIBERATE). J Eur Acad Dermatol Venereol 2017; 31: 507-517
• 34 Schett G, Wollenhaupt J, Papp K. et al. Oral apremilast in the treatment of active psoriatic arthritis: results of a multicenter, randomized, double-blind, placebo-controlledstudy. Arthritis Rheum 2012; 64: 3156-3167
• 35 Simpson EL, Imafuku S, Poulin Y. et al. A Phase 2 Randomized Trial of Apremilast in Patients with Atopic Dermatitis. J Invest Dermatol 2019; 139: 1036-1072
• 36 Dougados M, van der Heijde D, Chen YC. et al. Baricitinib in patients with inadequate response or intolerance to conventional synthetic DMARDs: results from the RA-BUILD study. Ann Rheum Dis 2017; 76: 88-95
• 37 Guttman-Yassky E, Silverberg JI, Nemoto O. et al. Baricitinib in adult patients with moderate-to-severe atopic dermatitis: a phase 2 parallel, double-blinded, randomized placebo-controlled multiple-dose study. J Am Acad Dermatol 2019; 80: 913-921.e9
• 38 Keystone EC, Genovese MC, Schlichting DE. et al. Safety and Efficacy of Baricitinib Through 128 Weeks in an Open-label, Longterm Extension Study in Patients with Rheumatoid Arthritis. J Rheumatol 2018; 45: 14-21
• 39 Keystone EC, Taylor PC, Drescher E. et al. Safety and efficacy of baricitinib at 24 weeks in patients with rheumatoid arthritis who have had an inadequate response to methotrexate. Ann Rheum Dis 2015; 74: 333-340
• 40 Papp KA, Menter MA, Raman M. et al. A randomized phase 2b trial of baricitinib, an oral Janus kinase (JAK) 1/JAK2 inhibitor, in patients with moderate-to-severe psoriasis. Br J Dermatol 2016; 174: 1266-1276
• 41 Tanaka Y, Emoto K, Cai Z. et al. Efficacy and Safety of Baricitinib in Japanese Patients with Active Rheumatoid Arthritis Receiving Background Methotrexate Therapy: A 12-week, Double-blind, Randomized Placebo-controlled Study. J Rheumatol 2016; 43: 504-511
• 42 Wallace DJ, Furie RA, Tanaka Y. et al. Baricitinib for systemic lupus erythematosus: a double-blind, randomised, placebo-controlled, phase 2 trial. Lancet 2018; 392: 222-231
• 43 Banham GD, Flint SM, Torpey N. et al. Belimumab in kidney transplantation: an experimental medicine, randomised, placebo-controlled phase 2 trial. Lancet. 2018 2018; 391: 2619-2630
• 44 Furie R, Petri M, Zamani O. et al.; BLISS-76 Study Group. A phase III, randomized, placebo-controlled study of belimumab, a monoclonal antibody that inhibits B lymphocyte stimulator, in patients with systemic lupus erythematosus. Arthritis Rheum 2011; 63: 3918-3930
• 45 Furie RA, Wallace DJ, Aranow C. et al. Long-Term Safety and Efficacy of Belimumab in Patients With Systemic Lupus Erythematosus: A Continuation of a Seventy-Six-Week Phase III Parent Study in the United States. Arthritis Rheumatol 2018; 70: 868-877
• 46 Gordon JK, Martyanov V, Franks JM. et al. Belimumab for the Treatment of Early Diffuse Systemic Sclerosis: Results of a Randomized, Double-Blind, Placebo-Controlled, Pilot Trial. Arthritis Rheumatol 2018; 70: 308-316
• 47 Merrill JT, Ginzler EM, Wallace DJ. et al. Long-term safety profile of belimumab plus standard therapy in patients with systemic lupus erythematosus. Arthritis Rheum 2012; 64: 3364-3373
• 48 Navarra SV, Guzmán RM, Gallacher AE. et al.; BLISS-52 Study Group. Efficacy and safety of belimumab in patients with active systemic lupus erythematosus: a randomised, placebo-controlled, phase 3 trial. Lancet 2011; 377: 721-731
• 49 Stohl W, Schwarting A, Okada M. et al. Efficacy and Safety of Subcutaneous Belimumab in Systemic Lupus Erythematosus: A Fifty-Two-Week Randomized, Double-Blind, Placebo-Controlled Study. Arthritis Rheumatol 2017; 69: 1016-1027
• 50 Krause K, Tsianakas A, Wagner N. et al. Efficacy and safety of canakinumab in Schnitzler syndrome: A multicenter randomized placebo-controlled study. J Allergy Clin Immunol 2017; 139: 1311-1320
• 51 Rissanen A, Howard CP, Botha J. et al. for the Global Investigators. Effect of anti-IL-1beta antibody (canakinumab) on insulin secretion rates in impaired glucose or type 2 diabetes: results of a randomized, placebo-controlled trial. Diabetes Obes Metab 2012; 14: 1088-1096
• 52 Ruperto N, Brunner HI, Quartier P. et al. Two randomized trials of canakinumab in systemic juvenile idiopathic arthritis. N Engl J Med 2012; 367: 2396-2406
• 53 Hensen J, Howard CP, Walter V. et al. Impact of interleukin-1β antibody (canakinumab) on glycaemic indicators in patients with type 2 diabetes mellitus: results of secondary endpoints from a randomized,placebo-controlled trial. Diabetes Metab 2013; 39: 524-531
• 54 Deodhar A, Poddubnyy D, Pacheco-Tena C. et al. Efficacy and Safety of Ixekizumab in the Treatment of Radiographic Axial Spondyloarthritis: Sixteen-Week Results From a Phase III Randomized, Double-Blind, Placebo-Controlled Trial in Patients With Prior Inadequate Response to or Intolerance of Tumor Necrosis Factor Inhibitors. Arthritis Rheumatol 2019; 71: 599-611
• 55 Gordon KB, Leonardi CL, Lebwohl M. et al. A 52-week, open-label study of the efficacy and safety of ixekizumab, an anti-interleukin-17A monoclonal antibody, in patients with chronic plaque psoriasis. J Am Acad Dermatol 2014; 71: 1176-1182
• 56 Gordon KB, Blauvelt A, Papp KA. et al. Phase 3 Trials of Ixekizumab in Moderate-to-Severe Plaque Psoriasis. N Engl J Med 2016; 375: 345-356
• 57 Griffiths CEM, Reich K, Lebwohl M. et al. Comparison of ixekizumab with etanercept or placebo in moderate-to-severe psoriasis (UNCOVER-2 and UNCOVER-3): results from two phase 3 randomised trials. Lancet 2015; 386: 541-551
• 58 Leonardi C, Matheson R, Zachariae C. et al. Anti-interleukin-17 monoclonal antibody ixekizumab in chronic plaque psoriasis. N Engl J Med 2012; 366: 1190-1199
• 59 Mease PJ, van der Heijde D, Ritchlin CT. et al. Ixekizumab, an interleukin-17A specific monoclonal antibody, for the treatment of biologic-naive patients with active psoriatic arthritis: results from the 24-week randomised, double-blind, placebo-controlled and active (adalimumab)-controlled period of the phase III trial SPIRIT-P1. Ann Rheum Dis 2017; 76: 79-87
• 60 Nash P, Kikham B, Okada M. et al. Ixekizumab for the treatment of patients with active psoriatic arthritis and an inadequate response to tumour necrosis factor inhibitors: results from the 24-week randomised, double-blind, placebo-controlled period of the SPIRIT-P2 phase 3 trial. Lancet 2017; 389: 2317-2327
• 61 van der Heijde D, Gladman DD, Kishimoto M. et al. Efficacy and Safety of Ixekizumab in Patients with Active Psoriatic Arthritis: 52-week Results from a Phase III Study (SPIRIT-P1). J Rheumatol 2018; 45: 367-377
• 62 Zachariae C, Gordon K, Kimball AB. et al. Efficacy and Safety of Ixekizumab Over 4 Years of Open-Label Treatment in a Phase 2 Study in Chronic Plaque Psoriasis. J Am Acad Dermatol 2018; 79: 294-301.e6
• 63 Baeten D, Sieper J, Braun J. et al. Secukinumab, an interleukin-17A inhibitor, in ankylosing spondylitis. N Engl J Med 2015; 373: 2534-2548
• 64 Baraliakos X, Kivitz AJ, Deodhar AA. et al. Long-term effects of interleukin-17A inhibition with secukinumab in active ankylosing spondylitis: 3-year efficacy and safety results from an extension of the Phase 3 MEASURE 1 trial. Clin Exp Rheumatol 2018; 36: 50-55
• 65 Braun J, Baraliakos X, Deodhar A. et al.; MEASURE 1 Study Group. Effect of secukinumab on clinical and radiographic outcomes in ankylosing spondylitis: 2-year results from the randomised phase III MEASURE 1 study. Ann Rheum Dis 2017; 76: 1070-1077
• 66 Genovese MC, Durez P, Richards HB. et al. One-year efficacy and safety results of secukinumab in patients with rheumatoid arthritis: phase II, dose-finding, double-blind, randomized, placebo-controlled study. J Rheumatol 2014; 41: 414-421
• 67 Gottlieb AB, Blauvelt A, Prinz JC. et al. Secukinumab Self-Administration by Prefilled Syringe Maintains Reduction of Plaque Psoriasis Severity Over 52 Weeks: Results of the FEATURE Trial. J Drugs Dermatol 2016; 15: 1226-1234
• 68 Kammüller M, Tsai T-F, Griffiths C. Inhibition of IL-17A by secukinumab shows no evidence of increased Mycobacterium tuberculosis infections. Clinical & Translational Immunology 2017; 6: e152
• 69 Kavanaugh A, Mease PJ, Reimold AM. et al.; FUTURE-1 Study Group. Secukinumab for Long-Term Treatment of Psoriatic Arthritis: A Two-Year Followup From a Phase III, Randomized, Double-Blind Placebo-Controlled Study. Arthritis Care Res (Hoboken) 2017; 69: 347-355
• 70 Lacour JP, Paul C, Jazayeri S. et al. Secukinumab administration by autoinjector maintains reduction of plaque psoriasis severity over 52 weeks: results of the randomized controlled JUNCTURE trial. J Eur Acad Dermatol Venereol 2017; 31: 847-856
• 71 Langley RG, Elewski BE, Lebwohl M. et al.; ERASURE Study Group; FIXTURE Study Group. Secukinumab in plaque psoriasis -- results of two phase 3 trials. N Engl J Med 2014; 371: 326-338
• 72 Marzo-Ortega H, Sieper J, Kivitz A. et al.; MEASURE 2 Study Group. Secukinumab and Sustained Improvement in Signs and Symptoms of Patients With Active Ankylosing Spondylitis Through Two Years: Results From a Phase III Study. Arthritis Care Res (Hoboken) 2017; 69: 1020-1029
• 73 McInnes IB, Mease PJ, Ritchlin CT. et al. Secukinumab sustains improvement in signs and symptoms of psoriatic arthritis: 2 year results from the phase 3 FUTURE 2 study. Rheumatology (Oxford) 2017; 56: 1993-2003
• 74 Mease PJ, McInnes IB, Kirkham B. et al.; FUTURE 1 Study Group. Secukinumab Inhibition of Interleukin-17A in Patients with Psoriatic Arthritis. N Engl J Med 2015; 373: 1329-1339
• 75 Pavelka K, Kivitz A, Dokoupilova E. et al. Efficacy, safety, and tolerability of secukinumab in patients with active ankylosing spondylitis: a randomized, double-blind phase 3 study, MEASURE 3. Arthritis Res Ther 2017; 19: 285
• 76 Rich P, Sigurgeirsson B, Thaci D. et al. Secukinumab induction and maintenance therapy in moderate-to-severe plaque psoriasis: a randomized, double-blind, placebo-controlled, phase II regimen-finding study. Br J Dermatol 2013; 168: 402-411
• 77 Tlustochowicz W, Rahman P, Seriolo B. et al. Efficacy and Safety of Subcutaneous and Intravenous Loading Dose Regimens of Secukinumab in Patients with Active Rheumatoid Arthritis: Results from a Randomized Phase II Study. J Rheumatol 2016; 43: 495-503
• 78 De Benedetti F, Brunner HI, Ruperto N. et al.; PRINTO; PRCSG. Randomized trial of tocilizumab in systemic juvenile idiopathic arthritis. N Engl J Med 2012; 367: 2385-2395 Erratum in: N Engl J Med 2015; 372 (9): 887
• 79 Emery P, Keystone E, Tony HP. et al. IL-6 receptor inhibition with tocilizumab improves treatment outcomes in patients with rheumatoid arthritis refractory to anti-tumour necrosis factor biologicals: results from a 24-week multicentre randomised placebo-controlled trial. Ann Rheum Dis 2008; 67: 1516-1523
• 80 Kremer JM, Blanco R, Brzosko M. et al. Tocilizumab inhibits structural joint damage in rheumatoid arthritis patients with inadequate responses to methotrexate: results from the double-blind treatment phase of a randomized placebo-controlled trial of tocilizumab safety and prevention of structural joint damage at one year. Arthritis Rheum 2011; 63: 609-621
• 81 Kivitz A, Wallace T, Olech E. et al. Long-Term Safety and Efficacy of Subcutaneously Administered Tocilizumab for Adult Rheumatoid Arthritis: A Multicenter Phase 3b Long-term Extension Study. Rheumatol Ther 2016; 3: 291-304
• 82 Kaneko Y, Kameda H, Ikeda K. et al. Tocilizumab in patients with adult-onset still's disease refractory to glucocorticoid treatment: a randomised, double-blind, placebo-controlled phase III trial. Ann Rheum Dis 2018; 77: 1720-1729
• 83 Kivitz A, Olech E, Borofsky M. et al. Subcutaneous tocilizumab versus placebo in combination with disease-modifying antirheumatic drugs in patients with rheumatoid arthritis. Arthritis Care Res (Hoboken) 2014; 66: 1653-1661
• 84 Sieper J, Porter-Brown B, Thompson L. et al. Assessment of short-term symptomatic efficacy of tocilizumab in ankylosing spondylitis: results of randomised, placebo-controlled trials. Ann Rheum Dis 2014; 73: 95-100
• 85 Stone JH, Tuckwell K, Dimonaco S. et al. Trial of Tocilizumab in Giant-Cell Arteritis. N Engl J Med 2017; 377: 317-328
• 86 Yokota S, Imagawa T, Mori M. et al. Efficacy and safety of tocilizumab in patients with systemic-onset juvenile idiopathic arthritis: a randomised, double-blind, placebo-controlled, withdrawal phase III trial. Lancet 2008; 371: 998-1006
• 87 Villiger PM, Adler S, Kuchen S. et al. Tocilizumab for induction and maintenance of remission in giant cell arteritis: a phase 2, randomised, double-blind, placebo-controlled trial. Lancet 2016; 387: 1921-1927
• 88 van der Heijde D, Strand V, Tanaka Y. et al. Tofacitinib in Combination with Methotrexate in Patients with Rheumatoid Arthritis: Clinical Efficacy, Radiographic and Safety Outcomes from the 24-Month Phase 3 ORAL Scan Study. Arthritis Rheumatol 2019; 71: 878-891
• 89 Bissonnette R, Papp KA, Poulin Y. et al. Topical tofacitinib for atopic dermatitis: a phase IIa randomized trial. Br J Dermatol 2016; 175: 902-911
• 90 Boyle DL, Soma K, Hodge J. et al. The JAK inhibitor tofacitinib suppresses synovial JAK1-STAT signalling in rheumatoid arthritis. Ann Rheum Dis 2015; 74: 1311-1316
• 91 Conaghan PG, Østergaard M, Bowes MA. et al. Comparing the effects of tofacitinib, methotrexate and the combination, on bone marrow oedema, synovitis and bone erosion in methotrexate-naive, early active rheumatoid arthritis: results of an exploratory randomised MRI study incorporating semiquantitative and quantitative techniques. Ann Rheum Dis 2016; 75: 1024-1033
• 92 Fleischmann R, Cutolo M, Genovese MC. et al. Phase IIb dose-ranging study of the oral JAK inhibitor tofacitinib (CP-690,550) or adalimumab monotherapy versus placebo in patients with active rheumatoid arthritis with an inadequate response to disease-modifying antirheumatic drugs. Arthritis Rheum 2012; 64: 617-629
• 93 Fleischmann R, Mysler E, Hall S. et al. Efficacy and safety of tofacitinib monotherapy, tofacitinib with methotrexate, and adalimumab with methotrexate in patients with rheumatoid arthritis (ORAL Strategy): a phase 3b/4, double-blind, head-to-head, randomised controlled trial. Lancet 2017; 390: 457-468
• 94 Genovese MC, van Vollenhoven RF, Wilkinson B. et al. Switching from adalimumab to tofacitinib in the treatment of patients with rheumatoid arthritis. Arthritis Res Ther 2016; 18: 145
• 95 Kremer JM, Bloom BJ, Breedveld FC. et al. The safety and efficacy of a JAK inhibitor in patients with active rheumatoid arthritis: Results of a double-blind, placebo-controlled phase IIa trial of three dosage levels of CP-690,550 versus placebo. Arthritis Rheum 2009; 60: 1895-1905 Erratum in: Arthritis Rheum 2012 May; 64 (5): 1487
• 96 Kremer J, Li ZG, Hall S. et al. Tofacitinib in combination with nonbiologic disease-modifying antirheumatic drugs in patients with active rheumatoid arthritis: a randomized trial. Ann Intern Med 2013; 159: 253-261
• 97 Kremer JM, Cohen S, Wilkinson BE. et al. A phase IIb dose-ranging study of the oral JAK inhibitor tofacitinib (CP-690,550) versus placebo in combination with background methotrexate in patients with active rheumatoid arthritis and an inadequate response to methotrexate alone. Arthritis Rheum 2012; 64: 970-981
• 98 Merola JF, Elewski B, Tatulych S. et al. Efficacy of tofacitinib for the treatment of nail psoriasis: Two 52-week, randomized, controlled phase 3 studies in patients with moderate-to-severe plaque psoriasis. J Am Acad Dermatol 2017; 77: 79-87
• 99 Papp KA, Krueger JG, Feldman SR. et al. Tofacitinib, an oral Janus kinase inhibitor, for the treatment of chronic plaque psoriasis: Long-term efficacy and safety results from 2 randomized phase-III studies and 1 open-label long-term extension study. J Am Acad Dermatol 2016; 74: 841-850
• 100 Papp KA, Bissonnette R, Gooderham M. et al. Treatment of plaque psoriasis with an ointment formulation of the Janus kinase inhibitor, tofacitinib: a Phase 2b randomized clinical trial. BMC Dermatol 2016; 16: 15
• 101 Papp KA, Menter A, Strober B. et al. Efficacy and safety of tofacitinib, an oral Janus kinase inhibitor, in the treatment of psoriasis: a Phase 2b randomized placebo-controlled dose-ranging study. Br J Dermatol 2012; 167: 668-677
• 102 Strand V, Burmester GR, Zerbini CA. et al. Tofacitinib with methotrexate in third-line treatment of patients with active rheumatoid arthritis: patient-reported outcomes from a phase III trial. Arthritis Care Res (Hoboken) 2015; 67: 475-483
• 103 Tanaka Y, Takeuchi T, Yamanaka H. et al. Efficacy and safety of tofacitinib as monotherapy in Japanese patients with active rheumatoid arthritis: a 12-week, randomized, phase 2 study. Mod Rheumatol 2015; 25: 514-521
• 104 Valenzuela F, Korman NJ, Bissonnette R. et al. Tofacitinib in patients with moderate to severe chronic plaque psoriasis: long-term safety and efficacy in an open-label extension study. Br J Dermatol 2018; 179: 853-862
• 105 van der Heijde D, Deodhar A, Wei JC. et al. Tofacitinib in patients with ankylosing spondylitis: a phase II, 16-week, randomised, placebo-controlled, dose-ranging study. Ann Rheum Dis 2017; 76: 1340-1347
• 106 van Vollenhoven RF, Fleischmann R, Cohen S. et al.; ORAL Standard Investigators. Tofacitinib or adalimumab versus placebo in rheumatoid arthritis. N Engl J Med 2012; 367: 508-519 Erratum in: N Engl J Med 2013 Jul 18; 369 (3): 293
• 107 Wallenstein GV, Kanik KS, Wilkinson B. et al. Effects of the oral Janus kinase inhibitor tofacitinib on patient-reported outcomes in patients with active rheumatoid arthritis: results of two Phase 2 randomised controlled trials. Clin Exp Rheumatol 2016; 34: 430-442
• 108 Winthrop KL, Wouters AG, Choy EH. et al. The Safety and Immunogenicity of Live Zoster Vaccination in Patients With Rheumatoid Arthritis Before Starting Tofacitinib: A Randomized Phase II Trial. Arthritis Rheumatol 2017; 69: 1969-1977
• 109 Yamanaka H, Tanaka Y, Takeuchi T. et al. Tofacitinib, an oral Janus kinase inhibitor, as monotherapy or with background methotrexate, in Japanese patients with rheumatoid arthritis: an open-label, long-term extension study. Arthritis Res Ther 2016; 18: 34
• 110 Zhang J, Tsai T-F, Lee M-G. et al. The efficacy and safety of tofacitinib in Asian patients with moderate to severe chronic plaque psoriasis: A Phase 3, randomized, double-blind, placebo-controlled study. J Dermatol Sci 2017; 88: 36-45
• 111 Feagan BG, Sandborn WJ, Gasink C. et al.; UNITI-IM-UNITi Study Group. Ustekinumab as Induction and Maintenance Therapy for Crohnʼs Disease. N Engl J Med 2016; 375: 1946-1960
• 112 Gottlieb A, Menter A, Mendelsohn A. et al. Ustekinumab, a human interleukin 12/23 monoclonal antibody, for psoriatic arthritis: randomised, double-blind, placebo-controlled, crossover trial. Lancet 2009; 373: 633-640
• 113 Igarashi A, Kato T, Kato M. et al. Efficacy and safety of ustekinumab in Japanese patients with moderate-to-severe plaque-type psoriasis: long-term results from a phase 2/3 clinical trial. J Dermatol 2012; 39: 242-252
• 114 Judson MA, Baughman RP, Costabel U. et al. Safety and efficacy of ustekinumab or golimumab in patients with chronic sarcoidosis. Eur Respir J 2014; 44: 1296-1307
• 115 Kavanaugh A, Puig L, Gottlieb AB. et al.; PSUMMIT 1 Study Group. Maintenance of Clinical Efficacy and Radiographic Benefit Through Two Years of Ustekinumab Therapy in Patients With Active Psoriatic Arthritis: Results From a Randomized, Placebo-Controlled Phase III Trial. Arthritis Care Res (Hoboken) 2015; 67: 1739-1749
• 116 Khattri S, Brunner PM, Garcet S. et al. Efficacy and safety of ustekinumab treatment in adults with moderate-to-severe atopic dermatitis. Exp Dermatol 2017; 26: 28-35
• 117 Kimball AB, Papp KA, Wasfi Y. et al.; PHOENIX 1 Investigators. Long-term efficacy of ustekinumab in patients with moderate-to-severe psoriasis treated for up to 5 years in the PHOENIX 1 study. J Eur Acad Dermatol Venereol 2013; 27: 1535-1545
• 118 Leonardi CL, Kimball AB, Papp KA. et al.; PHOENIX 1 study investigators. Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 1). Lancet 2008; 371: 1665-1674 Erratum in: Lancet 2008 May 31; 371 (9627): 1838
• 119 McInnes IB, Kavanaugh A, Gottlieb AB. et al.; PSUMMIT 1 Study Group. Efficacy and safety of ustekinumab in patients with active psoriatic arthritis: 1 year results of the phase 3, multicentre, double-blind, placebo-controlled PSUMMIT 1 trial. Lancet 2013; 382: 780-789
• 120 Papp KA, Langley RG, Lebwohl M. et al.; PHOENIX 2 study investigators. Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 52-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 2). Lancet 2008; 371: 1675-1684
• 121 Papp KA, Gordon KB, Langley RG. et al. Impact of previous biologic use on the efficacy and safety of brodalumab and ustekinumab in patients with moderate-to-severe plaque psoriasis: integrated analysis of the randomized controlled trials AMAGINE-2 and AMAGINE-3. Br J Dermatol 2018; 179: 320-328 Epub 2018 May 23. PubMed PMID: 29488226
• 122 Ritchlin C, Rahman P, Kavanaugh A. et al.; PSUMMIT 2 Study Group. Efficacy and safety of the anti-IL-12/23 p40 monoclonal antibody, ustekinumab, in patients with active psoriatic arthritis despite conventional non-biological and biological anti-tumour necrosis factor therapy: 6-month and 1-year results of the phase 3, multicentre, double-blind, placebo-controlled, randomised PSUMMIT 2 trial. Ann Rheum Dis 2014; 73: 990-999
• 123 Lebwohl M, Strober B, Menter A. et al. Phase 3 Studies Comparing Brodalumab with Ustekinumab in Psoriasis. N Engl J Med 2015; 373: 1318-1328
• 124 Saeki H, Kabashima K, Tokura Y. et al. Efficacy and safety of ustekinumab in Japanese patients with severe atopic dermatitis: a randomized, double-blind, placebo-controlled, phase II study. Br J Dermatol 2017; 177: 419-427
• 125 Sandborn WJ, Rutgeerts P, Gasink C. et al. Long-term efficacy and safety of ustekinumab for Crohn's disease through the second year of therapy. Aliment Pharmacol Ther 2018; 48: 65-77
• 126 Tsai TF, Ho JC, Song M. et al.; PEARL Investigators. Efficacy and safety of ustekinumab for the treatment of moderate-to-severe psoriasis: a phase III, randomized, placebo-controlled trial in Taiwanese and Korean patients (PEARL). J Dermatol Sci 2011; 63: 154-163
• 127 van Vollenhoven RF, Hahn BH, Tsokos GC. et al. Efficacy and safety of ustekinumab, an IL-12 and IL-23 inhibitor, in patients with active systemic lupus erythematosus: results of a multicentre, double-blind, phase 2,randomised, controlled study. Lancet 2018; 392: 1330-1339
• 128 Zhu X, Zheng M, Song M. et al. Efficacy and safety of ustekinumab in Chinese patients with moderate to severe plaque-type psoriasis: results from a phase 3 clinical trial (LOTUS). J Drugs Dermatol 2013; 12: 166-174
• 129 Colombel JF, Sands BE. et al. The safety of vedolizumab for ulcerative colitis and Crohnʼs disease. Gut 2017; 66: 839-851
• 130 Feagan BG, Rutgeerts P, Sands BE. et al.; GEMINI 1 Study Group. Vedolizumab as induction and maintenance therapy for ulcerative colitis. N Engl J Med 2013; 369: 699-710
• 131 Motoya S, Watanabe K, Ogata H. et al. Vedolizumab in Japanese patients with ulcerative colitis: A Phase 3, randomized, double-blind, placebo-controlled study. PLoS One 2019; 14: e0212989
• 132 Parikh A, Leach T, Wyant T. et al. Vedolizumab for the treatment of active ulcerative colitis: a randomized controlled phase 2 dose-ranging study. Inflamm Bowel Dis 2012; 18: 1470-1479
• 133 Parikh A, Fox I, Leach T. et al. Long-term clinical experience with vedolizumab in patients with inflammatory bowel disease. Inflamm Bowel Dis 2013; 19: 1691-1699
• 134 Sandborn WJ, Feagan BG, Rutgeerts P. et al.; GEMINI 2 Study Group. Vedolizumab as induction and maintenance therapy for Crohn's disease. N Engl J Med 2013; 369: 711-721
• 135 Sands BE, Sandborn WJ, Van Assche G. et al. Vedolizumab as Induction and Maintenance Therapy for Crohnʼs Disease in Patients Naïve to or Who Have Failed Tumor Necrosis Factor Antagonist Therapy. Inflamm Bowel Dis 2017; 23: 97-106
• 136 Park HJ, Choi BY, Sohn M. et al. Effects of Tumor Necrosis Factor-alpha Inhibitors on the Incidence of Tuberculosis. Korean J Clin Pharm 2018; 28: 333-341
• 137 Solovic I, Sester M, Gomez-Reino JJ. et al. The risk of tuberculosis related to tumour necrosis factor antagonist therapies: a TBNET consensus statement. Eur Respir J 2010; 36: 1185-1206
• 138 Smolen JS, Genovese MC, Takeuchi T. et al. Safety profile of baricitinib in patients with active rheumatoid arthritis with over 2 years median time in treatment. J Rheumatol 2019; 46: 7-18
• 139 Cantini F, Nannini C, Niccoli L. et al. Risk of Tuberculosis Reactivation in Patients with Rheumatoid Arthritis, Ankylosing Spondylitis, and Psoriatic Arthritis Receiving Non-Anti-TNF-Targeted Biologics. Mediators Inflamm 2017; 2017: 8909834
• 140 Cantini F, Blandizzi C, Niccoli L. et al. Systematic review on tuberculosis risk in patients with rheumatoid arthritis receiving inhibitors of Janus Kinases. Expert Opin Drug Saf 2020; 19: 861-872
• 141 Mariette X, Gottenberg JE, Ravaud P. et al. Registries in rheumatoid arthritis and autoimmune diseases:data from the French registries. Rheumatology (Oxford) 2011; 50: 222-229
• 142 Takahashi N, Kojima T, Kaneko A. et al. Longterm efficacy and safety of abatacept in patients with rheumatoid arthritis treated in routine clinical practice: effect of concomitant methotrexate after 24 weeks. J Rheumatol 2015; 42: 786-793
• 143 Kalb RE, Fiorentino DF, Lebwohl MG. et al. Risk of serious infection with biologic and systemic treatment of psoriasis: results from the Psoriasis Longitudinal Assessment and Registry (PSOLAR). JAMA Dermatology 2015; 151: 961-969
• 144 Redelman-Sidi G, Michielin O, Cervera C. et al. ESCMID Study Group for Infections in Compromised Hosts (ESGICH) consensus document on the safety of targeted and biological therapies: an infectious diseases perspective (immune checkpoint inhibitors, celladhesion inhibitors, sphingosine-1-phosphate receptor modulators and pro-teasome inhibitors). Clin Microbiol Infect 2018; 24 (Suppl. 95) e107
• 145 Winthrop KL, Mariette X, Silva JT. et al. ESCMID Study Group for Infections in CompromisedHosts (ESGICH) Consensus Document on the safety of targeted and biological therapies: anInfectious Diseases perspective (Soluble immune effector molecules [II]: agents targeting interleukins,immunoglobulins and complement factors). Clin Microbiol Infect 2018; 24 (Suppl. 02) S21-S40
• 146 Reinwald M, Silva JT, Mueller NJ. et al. ESCMID Study Group for Infections in Compromised Hosts (ESGICH)consensus document on the safety of targeted and biological therapies: aninfectious diseases perspective (Intracellular signaling pathways). ClinMicrobiol Infect 2018; 24: S53e70
• 147 Winthrop KL, Yamashita S, Beekmann SE. et al. Mycobacterial and other serious infections in patients receiving anti-tumor necrosis factor and other newly approved biologic therapies: Case finding through the emerging infections network. Clin Infect Dis 2008; 46: 1738-1740
• 148 Fowler E, Ghamrawi RI, Ghiam N. et al. Risk of tuberculosis reactivation during interleukin-17 inhibitor therapy for psoriasis: a systematic review. J Eur Acad Dermatol Venereol 2020; 34: 1449-1456
• 149 https://www.dgrh.de/Start/Publikationen/Empfehlungen/Medikation/
• 150 Menzies D, Adjobimey M, Ruslami R. et al. Four Months of Rifampin or Nine Months of Isoniazid for Latent Tuberculosis in Adults. N Engl J Med 2018; 379: 440-453
• 151 Khanna U, Ellis A, Galadari A. et al. Utility of Repeat Latent Tuberculosis Testing in Patients Taking Biologics [abstract]. Arthritis Rheumatol; 2019 71. Available at (Accessed August 1, 2020): https://acrabstracts.org/abstract/utility-of-repeat-latent-tuberculosis-testing-in-patients-taking-biologics/
• 152 Ya J, Khanna U, Havele S. et al. Utility of repeat latent tuberculosis testing with QuantiFERON‐TB Gold test in psoriasis patients treated with TNF‐α inhibitors at a single U. S. institution. Br J Dermatol 2020; 182: 800-802
• 153 Mrowietz U, Riedl E, Winkler S. et al. No reactivation of tuberculosis in patients with latent tuberculosis infection receiving ixekizumab: A report from 16 clinical studies of patients with psoriasis or psoriatic arthritis. J Am Acad Dermatol 2020; 83: 1436-1439 [Epub 2020 Jun 8]